NEOVACS: MEETING OF THE INTERNATIONAL SCIENTIFIC COMMITTEE OF NEOVACS – 06/13/2022 at 08:00


Paris, June 13, 2022 – 8 a.m. CET – Neovacs (Euronext Growth Paris: ALNEV) announces the meeting of its International Scientific Advisory Board.

In order to strengthen its scientific expertise in the treatment of autoimmune diseases and allergies, Néovacs has decided to seek support from an international scientific committee. On the initiative of Vincent SERRA, Scientific Director, Neovacs regularly sets up a dedicated Scientific Council with international experts, depending on the programs and issues selected to best advise the company in its choices. The establishment of this scientific committee was welcomed by the Board of Directors of Neovacs.

The last meeting of the Scientific Committee was held in particular in the presence of:

  • Professor Brigitte AUTRAN, Professor Emeritus, Immunology, Faculty of Medicine Sorbonne-Cimi-Paris University (Center for Research in Immunology and Infectious Diseases);

  • Dr Jean-Paul PRIEELS, former Vice-President of R&D at GSK, Independent Director of numerous Biotechnology companies;

  • Professor Sebastian AMIGORENA, Director of the Cancer Immunotherapy Center at Institut Curie, Head of the Immunity and Cancer Laboratory (U932), Member of the Academy of Sciences;

  • Laurent REBER, Head of the Asthma, Allergy and Immunotherapy laboratory (U1291), INSERM/Toulouse.

The managers of the various R&D projects and Olivier Dhellin, Director of Pharmaceutical Development, presented the various projects in progress to the committee.

During this meeting, the Scientific Committee focused on the major areas of development of Neovacs, in particular:

  • A focus on Allergy and on the IL4/IL13 and IgE program, the result of a collaboration with the Institut Pasteur, INSERM and the University of Toulouse;

  • Progress on modifications to the production process according to Good Practices, for the implementation of an injectable product in humans;

  • An analysis of the competitive landscape of products in development;

  • An update on product positioning and associated clinical development;

  • The future of business with Kinoid 3

    th

    generation, a new confidential program and avenues for the internalization of new preclinical programs.

The members of the scientific committee unanimously hailed the quality of the research programs and the very encouraging pre-clinical results on asthma, atopic dermatitis and food allergies. They appreciated the work aimed at obtaining a product that can be industrialized and injected into humans. They also recognized the transparency of the presentations made by the Neovacs teams, both on the progress made and the constraints associated with the programs and the solutions provided.

A new meeting of the Scientific Committee will take place on 2

n/a

semester 2022.

ABOUT NEOVACS

Neovacs is a French biotechnology company, listed on Euronext Growth since 2010, specializing in therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology called Kinoid®, patented until 2038, makes it possible to induce a polyclonal immune response, applicable in several indications. Neovacs has developed IFNα Kinoid for the treatment of lupus in a phase IIb clinical study. The main study has been completed, the full results were presented on the 13

th

2019 international lupus congress. The Company has also completed promising preclinical work with another therapeutic vaccine, IL-4/IL-13 Kinoid, for the treatment of allergies. The ambition of this “Kinoid® approach” is to enable patients to better tolerate a lifelong treatment which would be more effective, well tolerated and very flexible in its administration.

For more information :

www.neovacs.fr

Jérôme FABREGUETTES-LEIB

Investor Relations

[email protected]

01 53 67 36 78

Deborah SCHWARTZ

Financial Press Relations

[email protected]

01 53 67 36 35

s


This post has the “? Actusnews SECURITY MASTER” service.


– SECURITY MASTER Key:

yZyeaZtvk2vGl51vZMtqmpNsnGtox2nHbGiblJaZaZucbmmSmG1ibZfHZnBlnmto

– To check this key:

https://www.security-master-key.com.



Regulated information:


Inside information:

– Other press releases


Full and original press release in PDF format:

https://www.actusnews.com/news/74962-nvcs_cp_sab_s12022_vdef.pdf

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com



Source link -86